# US 2003/0083337 A1 · Optically active 3-[(2-piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0083337 A1
- Document ID: US20030083337A1
- Status: Published application
- Kind: A1
- Application number: 10/215,910
- Filed: 2002-08-09
- Published: 2003-05-01
- Earliest claimed: 1996-03-29
- Inventors: Harry R. Howard; Stephane Caron; Mavis D. Adam
- Web page: https://patentgrep.com/patent/US20030083337A1

## CPC

- C07D 207/26: 2-Pyrrolidones
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to optically active 3-[(2-piperazinylphenyl)methyl]-1-[4(trifluoromethylphenyl]-2-pyrrolidinones and pharmaceutically acceptable salts thereof, to processes for their preparation, to isotopically-labeled analogs thereof, to pharmaceutical compositions comprising them and to their medicinal use as selective antagonists of the 5-HT1D rector. The compounds of the invention are useful in treating depression, obsessive-compulsive disorder (OCD) and diseases, disorders or conditions for which a 5-HT1D receptor selective antagonist is therapeutically indicated.

## Claims

### Claim 1

The (−)-enantiomer of a compound of formula I:
12
and pharmaceutically acceptable salts thereof; wherein R is H or CH3.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein R is CH3.

### Claim 3 (depends on 1)

A compound according to claim 1 of formula II:
13
and pharmaceutically acceptable salts thereof; wherein R and H or CH3.

### Claim 4 (depends on 3)

A compound according to claim 3, wherein R is CH3.

### Claim 5 (depends on 4)

A compound according to claim 4 which is (−)-3(S)-([[2-(4-methyl-1-piperazinyl)phenyl]methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone and pharmaceutically acceptable salts thereof.

### Claim 6

An enantiomeric mixture of (−)-3(S)-([[2-(4-methyl-1-piperazinyl)phenyl]methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone and (+)-3(R)-[[2-(4-methyl-1-piperazinyl)phenyl]methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone, or pharmaceutically acceptable salts thereof; wherein the ratio of the 3(S)-enantiomer to the (R)-enantiomer is excess of 2:1.

### Claim 7 (depends on 6)

A mixture according to claim 6 wherein the ratio is in excess of 5:1.

### Claim 8 (depends on 6)

A mixture according to claim 6 wherein the ratio is 99:1 or greater.

### Claim 9

A process for the preparation of (−)-3(S)-([[2-(4-methyl-1-piperazinyl)phenyl]methyl]-1-[4trifluoromethyl)phenyl]-2-pyrrolidinone comprising the steps of:
(i) dissolving a compound of the formula I:
14
in an appropriate solvent in the presence of (+)di-p-toluoyl-D-tartaric acid;
(ii) collecting the solid precipitate comprising the salt of formula III:
15
and (iii) treating said precipitate with a base.

### Claim 10 (depends on 9)

The process according to claim 9, where R is CH3.

### Claim 11 (depends on 9)

A process according to claim 9 wherein the appropriate solvent in step (i) is selected from the group consisting of 2-butanone, acetone, 3-pentanone, methanol, ethanol, isopropanol, and ethyl acetate.

### Claim 12 (depends on 9)

A process according to claim 9 wherein the base is selected from the group consisting of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate, potassium bicarbonate, lithium hydroxide, and ammonium hydroxide.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 1)

A method for treating a disease, disorder or condition selected from depression, generalized anxiety disorder, phobias, post-traumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders, obesity, chemical dependencies, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, and gastrointestinal tract disorders where changes in motility and secretion are involved, in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound according to claim 1 that is effective in treating such disorder or condition.

### Claim 15 (depends on 1)

A method for treating a disease, disorder or condition that can be treated by enhancing serotonergic neurotransmission in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound according to claim 1, that is effective in treating such disease, disorder or condition.

### Claim 16 (depends on 1, 14)

A method according to claim 14 wherein the amount of a compound according to claim 1 is a serotonin receptor antagonizing effective amount

### Claim 17 (depends on 1, 15)

A method according to claim 15 wherein the amount of a compound according to claim 1 is a serotonin receptor antagonizing effective amount

### Claim 18 (depends on 1)

A pharmaceutical composition for treating a disease, disorder or condition that can be treated by enhancing serotonergic neurotransmission in a mammal, comprising:
a) a pharmaceutically acceptable carrier;
b) a compound according to claim 1; and
c) a 5-HT re-uptake inhibitor or a pharmaceutically acceptable salt thereof;
wherein the amount of the active compounds are such that the combination is effective in treating such disease, disorder or condition.

### Claim 19 (depends on 1)

A method for treating a disease, disorder or condition that can be treated by enhancing serotonergic neurotransmission in a mammal, comprising administering to a mammal requiring such treatment:
a) a compound according to claim 1; and
b) a 5-HT re-uptake inhibitor or a pharmaceutically acceptable salt thereof;
wherein the amounts of the active compounds are such that the combination is effective in treating such disease, disorder or condition.

### Claim 20 (depends on 1)

A method for treating a disease, disorder or condition that can be treated by enhancing serotonergic neurotransmission in a mammal, comprising administering to said mammal requiring such treatment:
a) a 5-HT1A antagonist or a pharmaceutically acceptable salt thereof; and
b) a compound according to claim 1 or a pharmaceutically acceptable salt thereof;
wherein the amounts of the active compounds are such that the combination is effective in treating such disease, disorder or condition.

### Claim 21 (depends on 18)

A pharmaceutical composition according to claim 18, wherein the 5-HT re-uptake inhibitor is sertraline or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 19)

A method according to claim 19, wherein the 5-HT re-uptake inhibitor is sertraline or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1)

A method for treating a disease, disorder of condition selected from depression, generalized anxiety disorder, phobias, post-traumatic stress syndrome, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, and gastrointestinal tract disorders where changes in motility and secretion are involved, in a mammal, comprising administering to a mammal requiring such treatment:
a) a compound according to claim 1; and
b) a 5-HT re-uptake inhibitor or a pharmaceutically acceptable salt thereof;
wherein the amounts of the active compounds are such that the combination is effective in treating such disorder or condition.

### Claim 24 (depends on 1)

A method for treating a disorder or condition selected from depression, generalized anxiety disorder, phobias, post-traumatic stress syndrome, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, and gastrointestinal tract disorders where changes in motility and secretion are involved, in a mammal, comprising administering to a mammal requiring such treatment:
a) 5-HT1A antagonist or a pharmaceutically acceptable salt thereof; and
b) a compound according to claim 1 or a pharmaceutically acceptable salt thereof;
wherein the amounts of the active compounds are such that the combination is effective in treating such ease, disorder or condition.

### Claim 25 (depends on 1)

A compound according to claim 1 wherein any of the carbon atoms is a 11C or a 14C, any of the hydrogen atoms is 3H or any of the fluorine atoms is 18F.

### Claim 26 (depends on 1)

A process according to claim 1 where in the compound of formula I any of the carbon atoms is a 11C, any of the hydrogen atoms is 3H or any of the fluorine atoms is 18F.

### Claim 27

A compound of formula V:
16
wherein R is H or CH3.

### Claim 28

A process for preparing a racemate of formula VIII:
17
comprising the step of treating a compound of formula XIV:
18
with a base.

### Claim 29 (depends on 28)

A process according to claim 28 wherein the base is selected from the group consisting of potassium t-butoxide, sodium methoxide, potassium methoxide, potassium ethoxide, sodium ethoxide, sodium isopropoxide, and potassium isopropoxide.

### Claim 30 (depends on 1)

An compound according to claim 1 wherein one or more hydrogen atoms is 3H.

### Claim 31 (depends on 1)

A compound according to claim 1 wherein R is —C3H3.

### Claim 32 (depends on 1)

A compound according to claim 1 wherein one or more of the fluorine atoms is 18F.

### Claim 33 (depends on 1)

A compound according to claim 1 wherein one or more of the carbon atoms is 11C or 14C.

### Claim 34 (depends on 1)

A compound according to claim 1 wherein one or more hydrogen atoms is 3H; or one or more of the fluorine atoms is 18F; or one or more of the carbon atoms is 11C or 14C; or any combination thereof.

### Claim 35 (depends on 34)

A method for the determination of the distribution in a tissue sample of the (−)-enantiomer of a compound of formula I:
19
wherein R is H or CH3;
comprising the step of incubating a compound according to claim 34 with said tissue sample.
